Compass Ion Advisors
XBI icon

Compass Ion Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Compass Ion Advisors’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$630K Buy
3,993
+117
+3% +$18.5K 0.05% 164
2026
Q2 		$613K Buy
3,876
+90
+2% +$12.2K 0.05% 167
2026
Q1 		$484K Sell
3,786
-100
-3% -$12.5K 0.05% 182
2025
Q4 		$474K Buy
3,886
+97
+3% +$11.1K 0.05% 182
2025
Q3 		$380K Buy
3,789
+62
+2% +$5.58K 0.04% 203
2025
Q2 		$309K Buy
3,727
+140
+4% +$11.2K 0.03% 209
2025
Q1 		$291K Sell
3,587
-247
-6% -$22.1K 0.03% 211
2024
Q4 		$345K Hold
3,834
– – 0.04% 198
2024
Q3 		$379K Buy
3,834
+2
+0.1% +$197 0.05% 190
2024
Q2 		$364K Hold
3,832
– – 0.05% 166
2024
Q1 		$364K Buy
3,832
+441
+13% +$40.9K 0.05% 165
2023
Q4 		$303K Hold
3,391
– – 0.05% 186
2023
Q3 		$248K Buy
+3,391
New +$271K 0.04% 202

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $72.8B AUM 32.97% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return
Natixis
Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return

Compass Ion Advisors's XBI Position: Q3 2026 in Review

Compass Ion Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 3% in Q3 2026, buying an estimated $18.5K and bringing the position to 3,993 shares worth $630K. The position accounts for 0.05% of the portfolio, ranked #164.

Compass Ion Advisors first reported a position in XBI in Q3 2023 and has held it in 13 quarters since. 721 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

  • Compass Ion Advisors held 3,993 shares of State Street SPDR S&P Biotech ETF worth $630K as of Q3 2026.
  • Compass Ion Advisors bought 117 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $18.5K.
  • State Street SPDR S&P Biotech ETF made up 0.05% of Compass Ion Advisors's portfolio in Q3 2026, its #164 holding.
  • Compass Ion Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q3 2023 and has held it in 13 quarters since.
  • 721 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Compass Ion Advisors's 13F filing for Q3 2026, filed 23 Oct 2026.